publication venue for
- A re-audit of HIV testing: where are we now? 2018
- Factors partitioning physical frailty in people aging with HIV: A classification and regression tree approach. 23:738-749. 2022
- Identification and characterization of HIV positive Ethiopian elite controllers in both Africa and Israel. 20:33-37. 2019
- Vitamin D and progression of carotid intima‐media thickness in HIV‐positive Canadians. 19:143-151. 2018
-
A tale of two countries: all‐cause mortality among people living with
HIV and receiving combination antiretroviral therapy in theUK and Canada. 18:655-666. 2017 -
Quality of initial
HIV care in Canada: extension of a composite programmatic assessment tool forHIV therapy. 18:151-160. 2017 -
Fibroblast growth factor 23: associations with antiretroviral therapy in patients co‐infected with
HIV and hepatitis C. 17:373-379. 2016 -
Opioid use and risk of liver fibrosis in
HIV /hepatitisC virus‐coinfected patients inC anada. 17:36-45. 2016 -
HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral‐treatedHIV /hepatitisC virus‐coinfected patients. 16:24-31. 2015 -
Characteristics and determinants of
T ‐cell phenotype normalization inHIV ‐1‐infected individuals receiving long‐term antiretroviral therapy. 15:153-164. 2014 -
Occult hepatitis
B virus coinfection inHIV ‐positiveA frican migrants to theUK : a point prevalence study. 15:189-192. 2014 -
Prevalence, clinical associations, and impact of intimate partner violence among
HIV ‐infected gay and bisexual men: a population‐based study. 14:293-302. 2013 -
HIV and hepatitisC virus coinfection inC anada: challenges and opportunities for reducing preventable morbidity and mortality. 14:10-20. 2013 - High prevalence of unintended pregnancies in HIV‐positive women of reproductive age in Ontario, Canada: a retrospective study. 13:107-117. 2012
- Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort. 12:352-360. 2011
- Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136)*. 10:116-124. 2009
- Antiretroviral effects on HIV‐1 RNA, CD4 cell count and progression to AIDS or death: a meta‐regression analysis. 9:849-857. 2008
- Male circumcision for the prevention of heterosexually acquired HIV infection: a meta‐analysis of randomized trials involving 11 050 men*. 9:332-335. 2008
- A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector® vs standard needles for enfuvirtide administration*. 8:427-432. 2007